The story
In 1996, Purdue Pharma, a privately held company owned by the Sackler family, launched OxyContin, a tablet of oxycodone designed to release the drug slowly over about 12 hours. The Food and Drug Administration had approved it in December 1995. Purdue promoted it for common pain, not only for cancer patients and the dying, and trained a large sales force to visit doctors, offering free trial coupons and sales bonuses. The labeling and marketing suggested that the slow-release design made addiction rare and that patients could be treated for long periods.
Opioids come from the opium poppy, and the active ingredient morphine had been isolated in the early 1800s; oxycodone was first synthesized in Germany in 1916. Doctors had long been wary of prescribing opioids for non-cancer pain because of addiction. In the 1980s and 1990s many pain specialists argued that pain was undertreated, and a 1980 five-sentence letter in the New England Journal of Medicine, which noted few addictions among hospitalized patients given opioids, was widely cited to support the claim that addiction risk was under one percent. Purdue used that environment, even though the data did not apply to long-term outpatient use.
Prescriptions rose steeply, and so did misuse. Crushing the tablet defeated the slow-release mechanism and gave a heroin-like rush. Overdose deaths from opioids climbed through the 2000s, and roughly 500,000 Americans died of opioid overdoses between 1999 and 2019. In 2007 Purdue and three executives pleaded guilty to misleading the public about addiction risk, and the company paid about 634 million dollars. As prescriptions were restricted, many users turned to heroin, and from about 2013 to illicit fentanyl, a far stronger synthetic opioid. Purdue filed for bankruptcy in 2019, and lawsuits by states and cities produced settlements worth billions.
Why it mattered
- Illicit fentanyl replaced prescription pills as the main driver of overdose deaths from about 2013, causing the deadliest wave of the crisis.
- Doctors and regulators tightened rules on opioid prescribing, including state monitoring programs and federal guidelines in 2016.
- Litigation against manufacturers and distributors produced tens of billions of dollars in settlements for states and local governments.
- U.S. life expectancy stalled and then fell in the 2010s, partly because of drug overdose deaths.
Sources
- Understanding the opioid overdose epidemic (CDC) CDC
- OxyContin maker and executives ordered to pay $634 million NPR
- Drug Overdose Deaths in the United States, 1999-2019 CDC NCHS
- Origins of the opioid crisis and its enduring impacts PMC / Quarterly Journal of Economics
- NEJM issues unusual warning for readers about 1980 letter on opioid addiction Retraction Watch
Drafted by AI (Claude) from the sources above and checked against them by AI; no historian has reviewed this page. Spot a mistake? Suggest a correction. How pages are made
Community notes
Loading notes…